NurExone’s Breakthrough Extends Spinal Injury Treatment Window

EnerSpar Corp. (TSE:NRX) has released an update.

NurExone Biologic Inc. has revealed encouraging findings from a preclinical study showing that its ExoPTEN treatment for spinal cord injuries can be effective even when administered up to a week post-injury, potentially expanding the patient treatment window and enhancing recovery prospects. This new data could have significant implications for clinical trial recruitment and treatment eligibility, addressing the global incidence of spinal cord injuries with more flexible therapeutic solutions.

For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.